Skip to site menu Skip to page content

Post-Curing on the Reduction of Cyclosiloxanes Contaminates

By Watson-Marlow Fluid Technology Group
Drug manufacturers are increasingly concerned about the sources of potential contamination from processing equipment. To give a sense of the scale of this problem, 15% of drug recalls reported by the US Food and Drug Administration (FDA) in the last six months were due to contamination from processing equipment. A primary area of concern is the direct contact of plastic processing materials that comprise single-use components with the drug product. It is widely known that this can result in the presence of compounds, which may affect efficacy, safety or quality. For manufacturers working on a multi-million dollar drug trials and treatments, the implications of this from a product development and brand integrity perspective are significant. Download this free white paper to find out more.
Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Related Content